The FDA has recently approved Krystal biotech's beremagene geperpavec (B-VEC, Vyjuvek) to treat the wounds of dystrophic epidermolysis bullosa (DEB) patients. This represents a giant step, not only toward the treatment of this devastating disease, but also for the whole field of non-replicative (nr) recombinant HSV-1 vectors for gene therapy. To view this Bench to Bedside, open or download the PDF.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cell.2023.07.031 | DOI Listing |
Publication Analysis
Top Keywords
gene therapy
8
dystrophic epidermolysis
8
epidermolysis bullosa
8
bullosa deb
8
herpes simplex
4
simplex virus
4
virus gene
4
therapy dystrophic
4
deb fda
4
fda approved
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!